Bioniche Life Science fka BNC (BNC)

[BioSpecialist]

BNC.TO is the next Dendreon !!!!!!!!!!!

Urocidin (Bladder cancer) PIII results in 2Q 2010

Positive Results will push this stock to 5$ ++ ....Please do your own DD !!

Bioniche Life Science (BNC.TO)

Market Cap: 81 Mio C$
Cash: 30 Mio C$
Price: 0,94 C$


Bioniche shares jump 34% on Endo taking up global rights
February 12, 2010 by biotuesday
http://biotuesday.ca/2010/02/12/bioniche-shares-jump-34-on-endo-taking-up-global-rights/


Upcoming Milestones

2009/2010 Conditional license for E. coli cattle vaccine in the U.S.

2009/2010 Achievement of pre-commercialization milestone payments for
UrocidinTM

2010 First U.S. sales of E. coli cattle vaccine

2010 Results of refractory Phase III NMI bladder cancer trial

2011 Belleville, ON vaccine manufacturing centre operational


Insider activity
http://canadianinsider.com/coReport/allTransactions.php?ticker=bnc


Urocidin (Bladder Cancer) PII Results
http://www.medicalnewstoday.com/articles/139517.php


1,50 $ TGT by Haywood
http://www.haywood.com/pdffiles/BNCJul142009.pdf


SECTOR OUTPERFORM; Target: $1.50 Risk: SPECULATIVE

Partnership Agreement Puts BNC Back on Track

ALPHA: We see significant upside to investors. BNC's share price

reflects a value for the Animal Health division only - that is at 5x

2009 EBITDA or
.50/shr. We note the US$20M upfront from the Endo

agreement is worth ~
.25/shr alone. We disagree with the market that

the Human Health division with Urocidin is currently worth zero to BNC and investors.